8Oishi Y,Ozono R,Yoshizumi M,et al. AT2 receptor mediates the cardioprotective effects of ATI receptor antagonist in postmyocardial infraction remodeling[J]. Life Sci, 2006,80(1) :82-88.
9Cohn J'N, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J]. N Engl JMed,2001,345:1667-1675.
10Mochizuki S,Dahlof B,Shimiozu M,et al. VaLsartan in a Japanese population with hypertension and other cardio vascular disease(Jikei Heart Study):a randomized, open label,blined endpoint morbidity-mortality study[J]. Lancet, 2007,369 : 1431-1439.
3Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling.Nature, 2002,415∶240-243.
4Greenberg B.J Treatment of heart failure∶state of the art and prospectives. Cardiovasc Pharmacol, 2001,38∶S59-S63.
5Hasegawa K, Iwaikanai E, Sasayama S. Neurohormonal regulation of myocardial cell apoptosis during the development of heart failure. J Cell Physiol, 2001,186∶11-18.
6Paull JR, Widdop RE.Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.J Hypertens 2001,19∶1393-1402.
7Molkentin JD, Gerald WD. Cytoplasmic signaling pathways that regulate cardiac hypertriophy. Annu Rev Physiol, 2001,63∶391-326.
8Yamazaki T, Komuro I, Zou Y. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α1 and β-adrenoceptors. Circulation, 1997,95∶1260-1268.
9Loppnow H, Westphal E, Buchhorn R, et al. Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock, 2001,16∶3-9.
10Takeshi A, Yoshihito T, Diane P, et al.Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat.Mol Cell Cardial, 2000,32∶1821-1830.
3Mochizuki S,Dahlfif B,Shimizu M,et al.Valsartan in a Japanesepopu-lation with hypertension and other cardiovascular disease(JikeiHeartStudy):a randomised,open-label,blinded endpoint morbidity-mortalitystudy[J].Lancet,2007,3(69):1431～1439
4Wong M, Staszewasky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study [ J ]. J Am Coll Cardiol, 2002, 40 (5) : 970 -975.
5McMurray JJ, Ostergren J, Swedberg K, et al. Effects of cande- sartan in patients with chronic heart failure and reduced left-ven- tricular systolic function taking' angiotensin converting enzyme in- hibitors: the CHARM-Added trial [ J]'. Lancet, 2003, 362 (9386) :767 -771.
6Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guide- line update for the diagnosis and management of chronic heart failure in the adult [ J]. Circulation, 2005, 112 ( 12 ) : 154 - 235.
7Athanasopoulos LV, Dritsas A, Doll HA, et al. Comparative value of NYHA functional class and quality of life questionnaire scores in assessing heart failure [ J ]. J Cardiopulm Rehabil Prev, 2010, 30(2) : 101 - 105.
8The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asympto-matic patients with reduced left ventricular ejection fractions [ J]. N Engl J Med, 1992, 327(10) : 685 -691.
9Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesar- tan in patients with chronic heart failure and reduced left-ven- tricular systolic function intolerant to angiotensin-converting-en- zyme inhibitors: the CHARM-Alternative trial[J]. The Lancet, 2003, 362(9386) :772 -776.
